Isis sees positive data in Phase II diabetes trial

Isis Pharmaceuticals says that data for its mid-stage trial of the diabetes drug Isis 113715 demonstrated improved blood sugar control in newly diagnosed patients but that blood sugar was not significantly improved. Patients taking 200 milligrams of the drug per week improved fasting blood glucose, fasting serum glucose and bad cholesterol. However, they did not see a significant improvement in hemoglobin A1c levels. The therapy, a second generation antisense drug, inhibits a protein that blocks insulin.

- read the AP report on Isis

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.